Ing. Jan Verner, Ph.D.
Research specialist, Vladimír Rotrekl Research Group
correspondence Address:
Kamenice 753/5, 625 00 Brno
office: bldg. F01B2/156
Kamenice 126/3
625 00 Brno
phone: | +420 549 49 5437 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 59
2019
-
Cílená inhibice kasein kinázy 1 v léčbě chronické lymfoidní leukémie.
Year: 2019, type: Conference abstract
-
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Haematologica, year: 2019, volume: 104, edition: 12, DOI
-
Potenciál inhibice proteinu checkpoint kinase 1 u chronické lymfocytární leukémie s mutacemi v genu TP53.
Year: 2019, type: Conference abstract
2018
-
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia
Blood, year: 2018, volume: 131, edition: 11, DOI
-
Development of selective casein kinase 1 delta/epsilon inhibitors for cancer
Year: 2018, type: Conference abstract
-
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53
Year: 2018, type: Conference abstract
-
Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
Year: 2018, type: Conference abstract
2017
-
Casein kinase 1 delta/epsilon inhibition blocks CLL chemotaxis and delays leukemia onset in the Eµ-TCL1 mouse model of chronic lymphocytic leukemia.
Year: 2017, type: Conference abstract
2016
-
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells
Oncotarget, year: 2016, volume: 7, edition: 38, DOI
2015
-
NOD/SCID IL2R gamma-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines
Leukemia & Lymphoma, year: 2015, volume: 56, edition: 11, DOI